Lack of interference of aspirin in HbA1c measured by ion-exchange HPLC in type 2 diabetic patients: A randomized, double-blind, placebo-controlled study

Camargo, Eduardo Guimarães; Pedrini, Renata Ortiz; Gross, Jorge Luiz; Camargo, Joíza Lins; Silveiro, Sandra Pinho

doi:10.1016/j.cca.2008.01.029

Cited by 6 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interindividual heterogeneity [28] a The effects of aspirin, vitamin C and vitamin E ingestion on the glycation of haemoglobin are disputed [89,90]. Despite the suggested impact of antiretrovirals on HbA 1c , recent evidence suggests the test is reasonably accurate in patients with HIV and diabetes [91].…”

Section: Reduced Erythropoiesismentioning

confidence: 99%

Current controversies in the use of haemoglobin A_1c

Hare

Shaw

Zimmet

2012

Journal of Internal Medicine

View full text Add to dashboard Cite

Abstract. Hare MJL, Shaw JE, Zimmet PZ (Baker IDI Heart and Diabetes Institute, Melbourne, Vic.; and Monash University, Melbourne, Vic.; Australia). Current controversies in the use of haemoglobin A 1c (Review). J Intern Med 2012;271: 227-236.Haemoglobin A 1c (HbA 1c ) has recently been adopted by the World Health Organization into its recommended criteria for diabetes diagnosis. Much debate continues regarding the relative benefits and potential disadvantages surrounding the use of HbA 1c for this purpose. There is a lack of consensus as to whether this alteration to the definition of diabetes is a step forward or whether it could add further confusion and ambiguity to the debate on the method and criteria for the diagnosis of this globally important disease. This review provides a comprehensive overview of the current issues surrounding how HbA 1c is measured and reported; and of the evidence for and against its use in diagnosis.

show abstract

Section: Reduced Erythropoiesismentioning

confidence: 99%

Current controversies in the use of haemoglobin A_1c

Hare

Shaw

Zimmet

2012

Journal of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…[20] reported an increase of 0.17% in the HbA1c of 28 non-diabetic subjects administered 200 mg of aspirin per day for 4 months. A subsequent study by the same author,[23] however, failed to show any interference of aspirin in the HbA1c (measured by ion-exchange HPLC) in type 2 diabetes patients. In clinical practice, the effect of aspirin on HbA1c is likely to be significant only when large doses are administered over a long period of time.…”

Section: Introductionmentioning

confidence: 97%

Drugs affecting HbA1c levels

Unnikrishnan

Anjana

Mohan

2012

Indian J Endocr Metab

View full text Add to dashboard Cite

Glycated hemoglobin (HbA1c) is an important indicator of glycemic control in diabetes mellitus, based on which important diagnostic and therapeutic decisions are routinely made. However, there are several situations in which the level of HbA1c may not faithfully reflect the glycemic control in a given patient. Important among these is the use of certain non-diabetic medications, which can affect the HbA1c levels in different ways. This review focuses on the non-diabetic medications which can inappropriately raise or lower the HbA1c levels, and the postulated mechanisms for the same.

show abstract

A meta-analysis of salicylates for type 2 diabetes mellitus

Fang

et al. 2013

J. Huazhong Univ. Sci. Technol. [Med. Sci.]

View full text Add to dashboard Cite

The aim of this study was to assess the effects and safety of salicylates on type 2 diabetes mellitus (T2DM). We searched six databases (Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CBM, CNKI and VIP) for all randomized controlled trials (RCTs) and self-control studies which investigated the effects of salicylates on T2DM. We included 34 RCTs and 17 self-control studies involving 13 464 patients with T2DM. It was demonstrated that salicylates had obvious effects on several parameters for patients with T2DM. (1) Any dose of salicylates could significantly reduce HbA1c level [mean difference (MD) -0.39%; 95% CI -0.47 to -0.32] in RCTs, but only high doses of salicylates (≥3000 mg/day) could effectively reduce fasting plasma glucose (FPG) level [standardized mean difference (SMD) -1.05; 95% CI -1.47 to -0.62] for patients with T2DM in both RCTs and self-control studies. Furthermore, high doses of salicylates could also increase plasma fasting insulin level (MD 12.20 mU/L; 95% CI 3.33 to 21.07); (2) In both RCTs and self-control studies, high doses of salicylates could significantly reduce plasma triglycerides concentration. The results for RCTs were MD -0.44 mmol/L, 95% CI -0.71 to -0.18, and those for self-control studies were 227±29 mg/dL (pre-treatment) and 117±8 mg/dL (post-treatment) (P=0.009); (3) All trials which reported cardiovascular events were RCTs using low doses (<1000 mg/day) of salicylates, and it was revealed that aspirin could significantly reduce the risk of myocardial infarction (OR 0.73; 95% CI 0.57 to 0.92); (4) Two RCTs and two self-control studies with ≥3000 mg/day salicylates reported adverse effects, and the overall effects were mild, and tinnitus occurred most frequently. No evidence of gastrointestinal bleeding was found in all these studies. In conclusion, from our systematic review, the anti-diabetic effect of salicylates is in a dose-dependent manner. High doses of salicylates may have beneficial effects on reducing FPG, HbA1c level and increasing fasting insulin concentration, and may also have some positive effects on lipidemia and inflammation-associated parameters for patients with T2DM, without serious adverse effects.

show abstract

Lack of interference of aspirin in HbA1c measured by ion-exchange HPLC in type 2 diabetic patients: A randomized, double-blind, placebo-controlled study

Cited by 6 publications

References 20 publications

Current controversies in the use of haemoglobin A_1c

Current controversies in the use of haemoglobin A_1c

Drugs affecting HbA1c levels

A meta-analysis of salicylates for type 2 diabetes mellitus

Contact Info

Product

Resources

About

Lack of interference of aspirin in HbA1c measured by ion-exchange HPLC in type 2 diabetic patients: A randomized, double-blind, placebo-controlled study

Cited by 6 publications

References 20 publications

Current controversies in the use of haemoglobin A1c

Current controversies in the use of haemoglobin A1c

Drugs affecting HbA1c levels

A meta-analysis of salicylates for type 2 diabetes mellitus

Contact Info

Product

Resources

About

Current controversies in the use of haemoglobin A_1c

Current controversies in the use of haemoglobin A_1c